國藥一致(000028.SZ)業績快報:2020年淨利升10.57%至14.02億元
格隆匯3月15日丨國藥一致(000028.SZ)披露2020年年度業績快報,2020年,公司實現營業收入596.49億元,同比增長13.00%;營業利潤21.64億元,同比增長18.21%;歸屬於上市公司股東的淨利潤14.02億元,同比增長10.57%;基本每股收益3.27元。
2020年,在新冠疫情以及藥品集採政策等的影響下,行業格局持續重構,集中度進一步提升,國藥一致統籌疫情防控與經營發展,紮實推進各項工作,不僅完成了抗疫保供的重大任務,且頂住了疫情帶來的巨大沖擊,經營業績再創歷史新高。
分銷板塊實現營業收入410.70億元,同比增長2.64%;實現淨利潤8.55億元,同比增長1.06%。零售板塊實現營業收入194.38億元,同比增長44.04%;實現淨利潤4.77億元,同比增長54.81%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.